N Leung

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. doi request reprint Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative
    Morie A Gertz
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 83:1131-8. 2008
  2. pmc Differences in immunoglobulin light chain species found in urinary exosomes in light chain amyloidosis (Al)
    Marina Ramirez-Alvarado
    Department of Biochemistry and Molecular Biology, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    PLoS ONE 7:e38061. 2012
  3. doi request reprint Myeloma-related kidney disease
    Nelson Leung
    Division of Nephrology and Hypertension, and Hematology, Mayo Clinic, Rochester, MN and Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN Electronic address
    Adv Chronic Kidney Dis 21:36-47. 2014
  4. doi request reprint Hematologic manifestations of kidney disease
    Nelson Leung
    Mayo Clinic, Division of Nephrology and Hypertension, and Division of Hematology, Rochester, MN, USA
    Semin Hematol 50:207-15. 2013
  5. pmc A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?
    Nelson Leung
    Division of Nephrology and Hypertension, Mayo Clinic, Rochester MN, USA
    Haematologica 98:988-92. 2013
  6. doi request reprint How I treat amyloidosis: the importance of accurate diagnosis and amyloid typing
    Nelson Leung
    Division of Nephrology and Hypertension, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
    Blood 120:3206-13. 2012
  7. pmc Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases
    Nelson Leung
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55901, USA
    Clin J Am Soc Nephrol 7:1964-8. 2012
  8. doi request reprint Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant
    Nelson Leung
    Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA
    Blood 120:4292-5. 2012
  9. ncbi request reprint Current approach to diagnosis and management of acute renal failure in myeloma patients
    Nelson Leung
    Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, USA
    Adv Chronic Kidney Dis 19:297-302. 2012
  10. pmc Treating myeloma cast nephropathy without treating myeloma
    Nelson Leung
    Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA
    J Clin Invest 122:1605-8. 2012

Detail Information

Publications71

  1. doi request reprint Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative
    Morie A Gertz
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 83:1131-8. 2008
    ..The overall 100-day survival rate was 98.9%. Our experience shows that outpatient transplant is feasible for all patients with multiple myeloma and results in shorter hospital stays and low treatment-related mortality rates...
  2. pmc Differences in immunoglobulin light chain species found in urinary exosomes in light chain amyloidosis (Al)
    Marina Ramirez-Alvarado
    Department of Biochemistry and Molecular Biology, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    PLoS ONE 7:e38061. 2012
    ..Our results showed that urinary exosomes may have tremendous potential in furthering our understanding of the pathophysiology and diagnosis of plasma cell dyscrasia related kidney diseases...
  3. doi request reprint Myeloma-related kidney disease
    Nelson Leung
    Division of Nephrology and Hypertension, and Hematology, Mayo Clinic, Rochester, MN and Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN Electronic address
    Adv Chronic Kidney Dis 21:36-47. 2014
    ..In some cases, direct invasion by myeloma cells and/or bone marrow cells can also result in kidney injury. A kidney biopsy can help distinguish the various myeloma-related kidney diseases and aid in the treatment plan. ..
  4. doi request reprint Hematologic manifestations of kidney disease
    Nelson Leung
    Mayo Clinic, Division of Nephrology and Hypertension, and Division of Hematology, Rochester, MN, USA
    Semin Hematol 50:207-15. 2013
    ..Finally, the failure of the kidney to clear toxins from the body can result in alteration involving hemostasis, as well as leukocyte function and survival. ..
  5. pmc A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?
    Nelson Leung
    Division of Nephrology and Hypertension, Mayo Clinic, Rochester MN, USA
    Haematologica 98:988-92. 2013
    ..In particular, discrimination of the renal response into complete and partial categories and modification of the serum creatinine requirement seem justified...
  6. doi request reprint How I treat amyloidosis: the importance of accurate diagnosis and amyloid typing
    Nelson Leung
    Division of Nephrology and Hypertension, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
    Blood 120:3206-13. 2012
    ....
  7. pmc Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases
    Nelson Leung
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55901, USA
    Clin J Am Soc Nephrol 7:1964-8. 2012
    ....
  8. doi request reprint Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant
    Nelson Leung
    Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA
    Blood 120:4292-5. 2012
    ....
  9. ncbi request reprint Current approach to diagnosis and management of acute renal failure in myeloma patients
    Nelson Leung
    Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, USA
    Adv Chronic Kidney Dis 19:297-302. 2012
    ..Reduction of serum free light chain is the key to recovery of renal function in these patients. The role of chemotherapy and extracorporeal removal of light chain are discussed...
  10. pmc Treating myeloma cast nephropathy without treating myeloma
    Nelson Leung
    Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA
    J Clin Invest 122:1605-8. 2012
    ..In animal studies, this cyclized peptide was capable of reducing cast formation and kidney injury, representing a novel treatment strategy for cast nephropathy that does not depend on the responsiveness of the myeloma to chemotherapy...
  11. doi request reprint Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney
    Alfonso Eirin
    Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA
    Nephrol Dial Transplant 27:1097-101. 2012
    ..There was a preference for ╬╗ light chain in the D-AL that was not noted in the V-AL. Patients with D-AL in this study had a longer median survival but most of them were stem cell transplantation candidates...
  12. ncbi request reprint Acute kidney injury in patients with inactive cytochrome P450 polymorphisms
    Nelson Leung
    Mayo Clinic Rochester, Division of Nephrology and Hypertension, Rochester, Minnesota, USA
    Ren Fail 31:749-52. 2009
    ..These are the first two cases of AKI associated with non-functional polymorphisms of cytochrome P450 superfamily. While the exact mechanism has not been worked out, it introduced the possibility of a new source of kidney injury...
  13. doi request reprint The outcome of patients with nephrogenic systemic fibrosis after successful kidney transplantation
    N Leung
    Division of Nephrology and Hypertension, Mayo Clinic Rochester, 200 First Street SW, Rochester, MN 55905, USA
    Am J Transplant 10:558-62. 2010
    ..Improvement in the dialysis patients was all partial. Successful KTx did not insure improvement in NSF and in fact appeared to have no significant benefit over dialysis...
  14. ncbi request reprint Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation
    Nelson Leung
    Division of Nephrology and Hypertension, Mayo Clinic Rochester, Rochester, Minnesota, USA
    Clin J Am Soc Nephrol 2:440-4. 2007
    ..Achievement of renal response was associated with improved survival. These results suggest that early intervention with aggressive therapy is not only justified but recommended to achieve optimal response...
  15. ncbi request reprint Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement
    Nelson Leung
    Department of Internal Medicine, Division of Nephrology and Hypertension, Mayo Clinic and Foundation, Rochester, MN, USA
    Am J Transplant 5:1660-70. 2005
    ..This experience supports the feasibility of sequential living donor KTx and autologous SCT for carefully selected patients with ESRD due to AL...
  16. ncbi request reprint Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation
    Nelson Leung
    Department of Medicine, Division of Nephrology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Kidney Dis 45:102-11. 2005
    ..The authors have noted the development of acute renal insufficiency immediately after melphalan conditioning. This study was undertaken to further examine its risk factors and impact on posttransplant mortality...
  17. doi request reprint Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains
    N Leung
    Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota 55905, USA
    Kidney Int 73:1282-8. 2008
    ..We found that the relationship between renal recovery and free light chain reduction was present only in patients with biopsy proven cast nephropathy showing the importance of extracorporeal light chain removal in this disease...
  18. ncbi request reprint Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients
    Nelson Leung
    Department of Medicine, Division of Nephrology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 106:3353-7. 2005
    ..The impact on mortality dissipated after the first year. Weight gain during mobilization appears to be a new marker of adverse outcome following HDM-SCT. Better prognostication may improve the treatment mortality rate of these patients...
  19. ncbi request reprint Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis
    Nelson Leung
    Division of Nephrology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Kidney Dis 46:270-7. 2005
    ..This study was undertaken to determine the prognostic importance of renal response after high-dose melphalan and stem cell transplantation...
  20. doi request reprint SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization
    M A Gertz
    Division of Hematology, Rochester, MN 55905, USA
    Bone Marrow Transplant 46:956-61. 2011
    ..The median hospital stay was 3.5 days shorter in the group not receiving growth factor. It is feasible and reasonable to perform autologous SCT for multiple myeloma without administering growth factors...
  21. doi request reprint Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis
    M A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 48:557-61. 2013
    ..Patients with serum troponin T >0.06 ng/mL or NT-proBNP >5000 pg/mL (not on dialysis) should not be considered candidates for SCT because of early mortality...
  22. pmc Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
    S K Kumar
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Leukemia 28:1122-8. 2014
    ..Most importantly, we demonstrate that the improved survival is benefitting older patients and that early mortality in this disease has reduced considerably. ..
  23. ncbi request reprint High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis
    A Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Heart 100:383-8. 2014
    ..To define whether the high sensitivity cardiac troponin T (hs-cTnT) assay in patients with immunoglobulin light chain amyloidosis (AL) improves risk prediction...
  24. ncbi request reprint Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis
    Robert J Hoyer
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 82:409-13. 2007
    ..Additional studies are needed to further define the role of bevacizumab in the management of this group of patients...
  25. ncbi request reprint Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma
    M A Gertz
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Bone Marrow Transplant 39:605-11. 2007
    ..Transplantation should be offered to selected patients over age 65 years or selected patients with creatinine elevation...
  26. ncbi request reprint Transplantation without growth factor: engraftment kinetics after stem cell transplantation for primary systemic amyloidosis (AL)
    M A Gertz
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 40:989-93. 2007
    ..Non-staphylococcal bacteremia was detected in 16% of patients. The median hospital stay was 9 days. It is feasible and reasonable to withhold growth factor therapy after autologous stem cell transplantation in patients with AL...
  27. doi request reprint Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006
    M A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Bone Marrow Transplant 46:970-5. 2011
    ..Improved supportive care and refined patient selection have improved the safety margin of patients undergoing auto-SCT; short-term mortality showed a more than 40% decrease after 2005...
  28. doi request reprint Long-term outcome of autologous stem cell transplantation in light chain deposition disease
    Elizabeth C Lorenz
    Division of Nephrology and Hypertension, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA
    Nephrol Dial Transplant 23:2052-7. 2008
    ..However, the impact of ASCT on renal function is unclear. This study retrospectively reviewed the effect of ASCT on renal function in patients with LCDD...
  29. ncbi request reprint Rituximab treatment of idiopathic membranous nephropathy
    F C Fervenza
    Division of Nephrology and Hypertension, Mayo Clinic, 200 First Street SW, Rochester, MN 55901, USA
    Kidney Int 73:117-25. 2008
    ..Rituximab appears effective in reducing proteinuria in some patients with idiopathic membranous nephropathy but prospective identification of responsive patients was not possible...
  30. ncbi request reprint Recurrent membranoproliferative glomerulonephritis after kidney transplantation
    Elizabeth C Lorenz
    Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Kidney Int 77:721-8. 2010
    ..Our study shows the risk of MPGN recurrence and progression depends on identifiable pretransplant characteristics, has variable clinical impact, and can result in graft failure...
  31. ncbi request reprint Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosupression
    M Gera
    Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Kidney Int 71:1296-301. 2007
    ..Potent antirejection regimes are well tolerated in these patients, are associated with a low risk of recurrence and an absence of AAV-related graft dysfunction...
  32. pmc Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement
    Sanjeev Sethi
    Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Clin J Am Soc Nephrol 6:1009-17. 2011
    ..A recently described entity referred to as GN with C3 deposition (GN-C3) bears many similarities to DDD. The purpose of this study was to evaluate AP function in cases of GN-C3...
  33. ncbi request reprint Acute granulomatous interstitial nephritis secondary to bisphosphonate alendronate sodium
    Lourdes Pena de la Vega
    Department of Internal Medicine, Division of Nephrology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Ren Fail 27:485-9. 2005
    ..Partial recovery of renal function occurred after 6 weeks of prednisone therapy and cyclophosphamide. This report describes a unique case of acute granulomatous interstitial nephritis and leukemic cell kidney infiltration by CLL...
  34. pmc Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy
    Sanjeev Sethi
    Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA
    Clin J Am Soc Nephrol 5:770-82. 2010
    ..Autoimmune diseases and chronic infections, such as hepatitis C, are commonly recognized causes of MPGN; however, monoclonal gammopathy is a less widely recognized cause of MPGN...
  35. pmc Rituximab therapy in idiopathic membranous nephropathy: a 2-year study
    Fernando C Fervenza
    Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, MN 55901, USA
    Clin J Am Soc Nephrol 5:2188-98. 2010
    ..This hypothesis was supported by previous pharmacokinetic (PK) analysis showing that RTX levels in the two-dose regimen were 50% lower compared with nonproteinuric patients, which could potentially result in undertreatment...
  36. pmc Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs
    Angela Dispenzieri
    Department of Medicine, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:757-9. 2010
    ....
  37. pmc Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis
    Sanjeev Sethi
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Clin J Am Soc Nephrol 5:2180-7. 2010
    ..We also describe the clinicopathologic findings of four problematic cases of renal Ig heavy chain amyloidosis that required LMD/MS proteomic analysis for accurate typing of the amyloid...
  38. ncbi request reprint Myeloablative chemotherapy and stem cell transplantation in myeloma or primary amyloidosis with renal involvement
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Kidney Int 68:1464-71. 2005
    ....
  39. pmc Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score
    Shaji K Kumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905
    Mayo Clin Proc 86:12-8. 2011
    ..To examine whether the outcome of patients with primary systemic amyloidosis (AL) has improved over time and to identify predictors of early mortality in patients with AL...
  40. pmc Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis
    Shaji K Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Minnesota, USA
    Am J Hematol 86:251-5. 2011
    ..It also highlights the importance of achieving at least a 90% reduction in the FLC-diff to improve the outcome of patients with light-chain AL...
  41. pmc Fibrillary glomerulonephritis: a report of 66 cases from a single institution
    Samih H Nasr
    Mayo Clinic, Division of Anatomic Pathology, Hilton 10 20, 200 First Street SW, Rochester, MN 55905, USA
    Clin J Am Soc Nephrol 6:775-84. 2011
    ..Most previously reported cases were idiopathic. To better define the clinical-pathologic spectrum and prognosis, we report the largest single-center series with the longest follow-up...
  42. ncbi request reprint Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia
    Tait D Shanafelt
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer 109:2291-8. 2007
    ..Although chemoimmunotherapy (CIT) has dramatically improved response rates in patients with CLL, some CIT regimens are not well tolerated by many patients >or=70 years of age...
  43. ncbi request reprint Serum uric acid: novel prognostic factor in primary systemic amyloidosis
    Shaji Kumar
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Mayo Clin Proc 83:297-303. 2008
    ..To determine the prognostic value of serum uric acid (UA) in patients with primary systemic (light chain) amyloidosis (AL)...
  44. ncbi request reprint Large sample of nephrogenic systemic fibrosis cases from a single institution
    Christine U Lee
    Department of Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Arch Dermatol 145:1095-102. 2009
    ....
  45. doi request reprint Safety and diagnostic yield of transjugular renal biopsy
    Sanjay Misra
    Department of Radiology, Mayo Clinic Rochester, 200 First St SW, Rochester, MN 55905, USA
    J Vasc Interv Radiol 19:546-51. 2008
    ..To evaluate the safety and tissue acquisition with transjugular renal biopsy (TJRB) by using the Quick-Core method in patients who were at high risk for complications with percutaneous renal biopsy...
  46. doi request reprint Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Nephrol Dial Transplant 24:3132-7. 2009
    ..The kidney is affected by immunoglobulin light chain amyloidosis (AL) in more than 50% of patients who present with the disease, but long-term predictors for and outcomes after renal replacement therapy are not well described...
  47. doi request reprint Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis
    Morie Gertz
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Lymphoma 49:36-41. 2008
    ..Those with troponin T levels exceeding 0.06 microg/L should be considered for less toxic therapies until the clinically optimal use of stem cell transplantation is better defined by randomized clinical trials...
  48. pmc Induction of heme oxygenase-1 and ferritin in the kidney in warm antibody hemolytic anemia
    Fernando C Fervenza
    Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, USA
    Am J Kidney Dis 52:972-7. 2008
    ..Finally, this case report documents that nephrotic-range proteinuria can occur in patients with autoimmune hemolytic anemia complicated by hemoglobinuria...
  49. ncbi request reprint Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response
    Morie A Gertz
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Haematologica 92:1415-8. 2007
    ..001), even after eliminating bias from early death. The degree of response was affected by the intensity of chemotherapy conditioning, septal thickness, and cardiac biomarkers. Hematologic response translates to longer survival...
  50. doi request reprint Bleeding complications after transcutaneous kidney biopsy in patients with systemic amyloidosis: single-center experience in 101 patients
    Sandra M Soares
    Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN 55902, USA
    Am J Kidney Dis 52:1079-83. 2008
    ..Amyloidosis is thought to be 1 of the risk factors, but this has not been confirmed in a large study. We performed this study to assess the risk of bleeding after kidney biopsy in patients with amyloidosis...
  51. pmc Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement--a prospective, open-label pilot trial
    Francisco Silva
    Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905, USA
    Clin J Am Soc Nephrol 5:445-53. 2010
    ..This prospective pilot trial explored whether mycophenolate mofetil (MMF) represents an effective alternative to CYC for induction and maintenance of remission in MPA with mild to moderate renal involvement...
  52. doi request reprint Coexistence of myeloma cast nephropathy, light chain deposition disease, and nonamyloid fibrils in a patient with multiple myeloma
    Qi Qian
    Department of Medicine, Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55902, USA
    Am J Kidney Dis 56:971-6. 2010
    ..We show that laser microdissection and mass spectrometry is an extremely useful ancillary test for the diagnosis of heavy and light chain deposition diseases...
  53. ncbi request reprint Changing incidence of glomerular disease in Olmsted County, Minnesota: a 30-year renal biopsy study
    Sundararaman Swaminathan
    Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Clin J Am Soc Nephrol 1:483-7. 2006
    ..1, 1.8, and 1.0 per 100,000/yr, respectively. This study confirms that the incidence of GN is growing overall, particularly for FSGS, which is the leading cause of nephrotic syndrome in white adults...
  54. ncbi request reprint Chronic renal dysfunction late after liver transplantation
    Ari J Cohen
    Department of Surgery, Division of Transplantation, Mayo Clinic, Rochester, MN 55905, USA
    Liver Transpl 8:916-21. 2002
    ..Patients with a low GFR at 1 year (< 40 mL/min/BSA) are a high-risk group that might benefit from early therapeutic interventions aimed at preventing subsequent renal failure...
  55. ncbi request reprint Acute cholestatic liver disease protects against glycerol-induced acute renal failure in the rat
    N Leung
    Department of Nephrology and Pathology, Mayo Clinic/Foundation, Rochester, Minnesota 55905, USA
    Kidney Int 60:1047-57. 2001
    ..We speculate that such potentially cytoprotective alterations may safeguard the kidney against irreversible functional and structural injury in the hepatorenal syndrome...
  56. ncbi request reprint Long-term outcome of renal transplantation in light-chain deposition disease
    Nelson Leung
    Division of Nephrology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Am J Kidney Dis 43:147-53. 2004
    ..A small number of kidney transplantations have been performed on LCDD patients in whom end-stage renal disease (ESRD) developed...
  57. doi request reprint Acute renal failure secondary to severe type I cryoglobulinemia following rituximab therapy for Waldenstr├Âm's macroglobulinemia
    Aisha Shaikh
    Division of Nephrology and Hypertension, Mayo Clinic Rochester, Rochester, MN, USA
    Clin Exp Nephrol 12:292-5. 2008
    ..As this case illustrates, the rituximab-induced cryoglobulin is not always benign. Pre- and post-treatment monitoring of the cryoglobulin level is advised in these patients...
  58. ncbi request reprint Renal manifestations of plasma cell disorders
    Nelson Leung
    Division of Nephrology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Am J Kidney Dis 50:155-65. 2007
  59. ncbi request reprint Approach to acute renal failure in biopsy proven myeloma cast nephropathy: is there still a role for plasmapheresis?
    Luana Pillon
    Department of Medicine, VA New York Harbor Health Care Systems, New York, New York, USA
    Kidney Int 74:956-61. 2008
  60. ncbi request reprint Renal failure due to combined cast nephropathy, amyloidosis and light-chain deposition disease
    Elizabeth C Lorenz
    Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA
    Nephrol Dial Transplant 25:1340-3. 2010
    ..We report a case of renal failure in a patient with MM caused by concurrent CN, amyloidosis and LCDD which has not been previously described...
  61. doi request reprint Long-term outcome of kidney transplantation in patients with fibrillary glomerulonephritis or monoclonal gammopathy with fibrillary deposits
    Peter G Czarnecki
    Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Kidney Int 75:420-7. 2009
    ..Whether the development of hematological malignancies following transplantation in this group is related to their original disease or was coincidental requires further studies...
  62. pmc Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis
    Tanya L Poshusta
    Department of Biochemistry and Molecular Biology, College of Medicine, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 4:e5169. 2009
    ..We hypothesize that location rather than number of non-conservative mutations determines the amyloidogenicity of light chains...
  63. doi request reprint Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation
    Sandra M S Herrmann
    Division of Nephrology and Hypertension, Mayo Clinic Rochester, Rochester, MN, USA
    Nephrol Dial Transplant 26:2032-6. 2011
    ..Kidney transplantation (KTx) has become more common but the long-term outcomes remain unknown and it is the objective of this study...
  64. pmc Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome
    Trista Stankowski-Drengler
    Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Am J Hematol 85:431-4. 2010
    ..In summary, serum immunoglobulin profiles are unique in POEMS syndrome as compared with other plasma cell disorders...
  65. ncbi request reprint Wegener's granulomatosis presenting as multiple bilateral renal masses
    Nelson Leung
    Division of Nephrology, Ei S24, Mayo Clinic Rochester, 200 First Street SW, Rochester, MN 55905, USA
    Nephrol Dial Transplant 19:984-7. 2004
  66. ncbi request reprint Recurrent Goodpasture's disease secondary to a monoclonal IgA1-kappa antibody autoreactive with the alpha1/alpha2 chains of type IV collagen
    Dorin Bogdan Borza
    Division of Nephrology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
    Am J Kidney Dis 45:397-406. 2005
    ..The specificity of an IgA antibody implicated in the pathogenesis of anti-GBM disease has been investigated for the first time, identifying the alpha1/alpha2(IV) collagen chains as a novel target for nephritogenic antibodies...
  67. ncbi request reprint Nephrogenic fibrosing dermopathy: lessons from the past
    Sundararaman Swaminathan
    Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota 55902, USA
    Int J Dermatol 45:639-41. 2006
  68. ncbi request reprint Plasma exchange in multiple myeloma
    Nelson Leung
    Ann Intern Med 144:455; author reply 455. 2006
  69. ncbi request reprint Isolation and biochemical characterization of plasma monoclonal free light chains in amyloidosis and multiple myeloma: a pilot study of intact and truncated forms of light chains and their charge properties
    Batia Kaplan
    Heller Institute of Medical Research, Sheba Medical Center, Tel Hashomer, Israel
    Clin Chem Lab Med 46:335-41. 2008
    ..The present study focused on the development of the procedure for isolation and biochemical characterization of monoclonal FLC in small plasma specimens from patients with these disorders...
  70. ncbi request reprint A tale of two markers
    Nelson Leung
    Liver Transpl 8:600-2. 2002
  71. ncbi request reprint Acute renal failure after liver transplantation: the role of dopamine and fenoldopam
    Nelson Leung
    Liver Transpl 10:993-4. 2004